论文信息 - Deprenyl in 6-Pyruvoyl Tetrahydropterin Synthase Deficiency - 字舞流文

Deprenyl in 6-Pyruvoyl Tetrahydropterin Synthase Deficiency

Á. Schuler | N. Blau | M. Spada | A. Ponzone | S. Ferraris | C. Lanza | A. Ponzone | A. Schuler

[1] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[2] M Schulzer,et al. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic , 1992, Annals of neurology.

[3] C. Olanow,et al. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? , 1992, Neurology.

[4] G. Mammen,et al. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. , 1991 .

[5] N. Blau,et al. Screening and treatment of tetrahydrobiopterin deficiency , 1990 .

[6] J. Langston,et al. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. , 1990, European journal of pharmacology.

[7] A. Boulton,et al. Possible mechanism of action of deprenyl in parkinsonism , 1990, The Lancet.

[8] J. Knoll,et al. Deprenyl (selegiline): the history of its development and pharmacological action , 1983, Acta neurologica Scandinavica. Supplementum.

[9] G. Reynolds,et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. , 1978, British journal of clinical pharmacology.

[10] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.